Notice for nivolumab (Bristol-Myers Squibb Australia Pty Ltd)
Active ingredients
nivolumab
Date of review outcome
Lapse date
Type
Priority Review
Indication
For the adjuvant treatment of Stage III/IV melanoma in patients who have undergone complete resection.
Registration date